Moffitt Cancer Center has announced that G. Douglas Letson, M.D., has been appointed the new executive vice president for Clinical Affairs and physician-in-chief, and Johnathan Lancaster, M.D., Ph.D., has been appointed the new president of the Moffitt Medical Group.In February, Moffitt announced that President and Chief Executive Officer William S. Dalton, Ph.D., M.D., will become the new CEO of M2Gen and lead the new Personalized Medicine Institute. M2Gen is a wholly owned, for-profit subsidiary of Moffitt, and the institute will focus on personalizing cancer care.
Alan List, M.D., executive vice president and physician-in-chief, will become CEO of Moffitt. Thomas A. Sellers, Ph.D., will become center director. All appointments will take effect in July.
